August 2011: 4th Round Capital Increase

Due to a better organization and efficiency of the sales team, Rondol sales have progressed rapidly with an average monthly order intake around 200K£ since September 2010 vs.70K in average over the previous 18 months.

The Rondol board has therefore decided to implement a further capital increase (300k£) in order to support further marketing investments in the pharma sector as well as the establishment of a technical office in Continental Europe. The capital increase was completed in August. Marzac Investment contributed 83% to this capital increase and now owns 39,8% of the company.

Gérard Tardy, former CEO of Schröders Capital, board member of several medtech and healthcare companies states and private investor in Rondol states: “ Rondol has made great progress with first class industrial customers, especially in Germany and the US.”